The National Institutes for Health (NIH) will grant Emory University more $1 million annually for the next five years to renew its support for Emory’s Morris K. Udall Center of Excellence in Parkinson’s Disease Research, aiming to fund the development of more effective Parkinson’s disease treatments that have…
Visual hallucinations are frequent among Parkinson’s disease patients, confirms a study published in the Journal of Neurological Sciences. In addition, it shows that visual hallucinations are associated with the duration of the disease, the use of dopamine agonist drugs, the quality of sleep, and the patients’ ability to think. According to the authors, these results “should trigger further inquiry by neurologists”.
Researchers at Wenzhou Medical University in China recently reviewed literature related to iron levels in the brains of patients with Parkinson’s disease (PD) and confirmed elevated levels in several regions of the brain. The review paper, “Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and…
Researchers in Ireland are reporting that people with Parkinson’s disease (PD) are being admitted to hospitals at increasing rates for serious but often preventable conditions — most often, urinary and respiratory tract infections, pneumonia, and fractures of the femur. The study, “Acute Hospital Admissions of Individuals with a Known …
Mutations in the LRRK2 gene, which have been associated with a high risk of Parkinson’s disease, may affect neurons by promoting cell death through the activation of a protein called PIG3, according to results of a study presented at the recent Society for Neuroscience 2016 meeting in San Diego. The study’s…
Several factors contribute to the outcome of patients with Parkinson’s disease who undergo deep brain stimulation (DBS), according to a new study. The research paper, “Short-term Adverse Outcomes Following Deep Brain Stimulation Treatment in Parkinson’s Disease Patients,” was published in the journal World Neurosurgery. DBS is a…
Prothena‘s potentially disease-modifying treatment for Parkinson’s disease, PRX002, met the primary objective in a Phase 1b multiple ascending dose clinical trial. The drug was found to be safe and well tolerated. PRX002 was also found to deeply penetrate the central nervous system in all doses tested. Levels of free…
A new method to encapsulate single cells in alginate hydrogels, a material derived from a sugar naturally-occurring in brown seaweed, could improve the delivery of therapeutic substances to the body and be used for the treatment of many diseases including Parkinson’s disease, according to a study published in the leading scientific journal Nature Materials.
International Stem Cell Corporation discussed advance work, leading to the first clinical trial to explore parthenogenetic stem cell transplants for patients with Parkinson’s disease, at the ongoing Society for Neuroscience 2016 Annual Meeting in San Diego. The presentation, “Transplantation of neural stem cells for parkinson’s disease, an update of the first-in-human clinical…
Researchers at Mayo Clinic’s campus in Florida have found a genetic mutation that may increase the risk for developing Parkinson’s disease earlier than usual. The study, “Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism,” was published in the journal Brain. The result of a…
Get regular updates to your inbox.